Uveitis News and Research

RSS
Uveitis is an inflammation of the uvea. The uvea is the front part of the eye. It includes the iris, which is the colored part of the eye, and the parts right next to and behind the iris. Uveitis may hurt a lot of parts of the eye. It may last as long as six weeks, or it may last a shorter time.
Physician-researchers find link between 'dry eye' and chronic pain syndromes

Physician-researchers find link between 'dry eye' and chronic pain syndromes

Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck expand oncology clinical trial collaboration

Lilly, Merck expand oncology clinical trial collaboration

TxCell reviews its manufacturing strategy to focus on R&D and strategic partnerships - its core, high added value businesses

TxCell reviews its manufacturing strategy to focus on R&D and strategic partnerships - its core, high added value businesses

FDA grants Orphan Drug Designation to TxCell's Col-Treg for treatment of autoimmune uveitis

FDA grants Orphan Drug Designation to TxCell's Col-Treg for treatment of autoimmune uveitis

NEI experts explore long-term effects of Ebola on the eye

NEI experts explore long-term effects of Ebola on the eye

Global urinary catheters market to expand at 4.1% CAGR between 2015 and 2021

Global urinary catheters market to expand at 4.1% CAGR between 2015 and 2021

Bacteria in gut may be the cause of uveitis in the eye

Bacteria in gut may be the cause of uveitis in the eye

New study suggests novel ways to treat serous retinal detachment

New study suggests novel ways to treat serous retinal detachment

OphthaliX updates website to reflect proposed acquisition of Israel-based Improved Vision Systems

OphthaliX updates website to reflect proposed acquisition of Israel-based Improved Vision Systems

Apitope's ATX-F8-117 granted FDA Orphan Drug Designation for treatment of haemophilia A patients

Apitope's ATX-F8-117 granted FDA Orphan Drug Designation for treatment of haemophilia A patients

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

TxCell to deliver two presentations on Col-Treg and Ovasave at ISCT Annual Meeting

TxCell to deliver two presentations on Col-Treg and Ovasave at ISCT Annual Meeting

TxCell presents preclinical efficacy and tolerability data for Col-Treg at 2015 ARVO Annual Meeting

TxCell presents preclinical efficacy and tolerability data for Col-Treg at 2015 ARVO Annual Meeting

TxCell to present at upcoming US and French investment conferences

TxCell to present at upcoming US and French investment conferences

TxCell invited to speak at largest US meeting for investors in emerging growth companies

TxCell invited to speak at largest US meeting for investors in emerging growth companies

TxCell to highlight success factors in cell therapy research at Cell & Gene Therapy Forum 2015

TxCell to highlight success factors in cell therapy research at Cell & Gene Therapy Forum 2015

EC grants orphan drug designation to TxCell's Col-Treg for treatment of autoimmune uveitis

EC grants orphan drug designation to TxCell's Col-Treg for treatment of autoimmune uveitis

Apitope's ATX-F8-117 granted orphan medicinal product designation for treatment of haemophilia A

Apitope's ATX-F8-117 granted orphan medicinal product designation for treatment of haemophilia A

TxCell demonstrates therapeutic potential of Col-Treg for treatment of autoimmune uveitis

TxCell demonstrates therapeutic potential of Col-Treg for treatment of autoimmune uveitis